{'fraction_non_alphanumeric': 0.0326530612244898, 'fraction_numerical': 0.02040816326530612, 'mean_word_length': 5.54, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunohistochemical study of monoclonal antibody MGD‐1 in gastric carcinoma

This paper reports a pathological and immunohistochemical study of gastric carcinoma for immunoreactivity with a monoclonal antibody, MGD‐1, raised against cells from an adenocarcinoma of stomach. Fifty‐four of 61 gastric carcinomas (89%) were positive for MGD‐1. Metastatic gastric carcinoma in local nodes was positive in all 11 such cases. Out of 40 examples of chronic atrophic gastritis, only three, with mild dysplasia, were positive (7.5%). Forty cases with normal gastric mucosa were negative. The MGD‐1 detection‐rate of well‐ and poorly‐differentiated gastric carcinoma was 85% and 93% respectively. The metastatic cells and cells infiltrating the submucosa and muscular layer were more frequently positive and showed stronger staining with MGD‐1 than those in mucosa. These results show that MGD‐1 possesses a high degree of specificity for gastric carcinoma and could be used diagnostically.